
浏览全部资源
扫码关注微信
武汉市中医医院脾胃肝胆病科,武汉 430010
主治医师,硕士。研究方向:中医内科临床。电话:027-84476811。E-mail:712102382@qq.com
副主任医师,硕士。研究方向:脾胃病和胃肠道疾病。电话:027-84476811。E-mail:49553327@qq.com
收稿日期:2024-03-18,
修回日期:2024-08-01,
录用日期:2024-08-01,
纸质出版日期:2024-09-15
移动端阅览
梁金,许丹,杜进军.车叶草苷对非酒精性脂肪性肝病大鼠肝纤维化的影响及机制 [J].中国药房,2024,35(17):2102-2107.
LIANG Jin,XU Dan,DU Jinjun.Effect and mechanism of asperuloside on liver fibrosis in non-alcoholic fatty liver rats[J].ZHONGGUO YAOFANG,2024,35(17):2102-2107.
梁金,许丹,杜进军.车叶草苷对非酒精性脂肪性肝病大鼠肝纤维化的影响及机制 [J].中国药房,2024,35(17):2102-2107. DOI: 10.6039/j.issn.1001-0408.2024.17.08.
LIANG Jin,XU Dan,DU Jinjun.Effect and mechanism of asperuloside on liver fibrosis in non-alcoholic fatty liver rats[J].ZHONGGUO YAOFANG,2024,35(17):2102-2107. DOI: 10.6039/j.issn.1001-0408.2024.17.08.
目的
2
探究车叶草苷调节鞘氨醇激酶1(SphK1)/1-磷酸鞘氨醇(S1P)信号通路对非酒精性脂肪性肝病(NAFLD)大鼠肝纤维化的影响及机制。
方法
2
以高脂饲料饲养的方法建立大鼠NAFLD模型,将造模成功的大鼠随机分为模型组、车叶草苷低剂量组(14 mg/kg,灌胃,下同)、车叶草苷高剂量组(28 mg/kg)、车叶草苷高剂量(28 mg/kg)+pc-NC(空载质粒,50 µg,尾静脉注射,下同)组、车叶草苷高剂量(28 mg/kg)+pc-SphK1(SphK1过表达质粒,50 µg)组,每组12只。另取12只大鼠以正常饲料饲养作为对照组。各组大鼠灌胃或尾静脉注射相应药物或质粒,灌胃处理每天1次,尾静脉注射处理每周2次,均连续3周。末次给药后,检测各组大鼠血脂指标[总胆固醇(TC)、甘油三酯(TG)、游离脂肪酸(FFA)
]
与肝功能指标[天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)
]
水平;观察大鼠肝组织病理变化以及肝纤维化情况;检测大鼠血清纤维化相关因子[Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-Col)、层粘连蛋白(LN)
]
、促纤维化因子[转化生长因子β
1
(TGF-β
1
)
]
与促炎因子[白细胞介素1β(IL-1β)、诱导型一氧化氮合酶(iNOS)、IL-6
]
水平;检测大鼠肝组织胶原形成相关蛋白(Ⅰ-Col、Ⅳ-Col)与SphK1/S1P信号通路相关蛋白表达。
结果
2
与对照组比较,模型组大鼠肝组织呈现明显病理损伤症状;NAFLD活动度评分、肝组织胶原容积分数(CVF)和血清中TC、TG、FFA、AST、ALT、PCⅢ、Ⅳ-Col、LN、TGF-β
1
、IL-1β、iNOS、IL-6水平以及肝组织中Ⅰ-Col、Ⅳ-Col、SphK1、S1P蛋白表达水平均显著升高(
P
<0.05)。与模型组比较,车叶草苷低、高剂量组大鼠肝组织病理损伤症状均减轻,上述指标水平均显著降低(
P
<0.05),且高剂量组降低效果更好(
P
<0.05)。与车叶草苷高剂量组和车叶草苷高剂量+pc-NC组比较,车叶草苷高剂量+pc-SphK1组大鼠肝组织病理损伤症状加重,上述指标水平均显著升高(
P
<0.05)。
结论
2
车叶草苷可通过抑制SphK1/S1P信号通路活性,降低促纤维化因子、促炎因子以及胶原形成蛋白表达,从而减轻NAFLD大鼠肝纤维化。
OBJECTIVE
2
To investigate the effect and mechanism of asperuloside on liver fibrosis in non-alcoholic fatty liver disease (NAFLD) rats by regulating the sphingosine kinase 1 (SphK1)/sphingosine-1-phosphate (S1P) signaling pathway.
METHODS
2
SD rats were fed with a high-fat diet to establish a NAFLD model. They were randomly separated into model group, asper
uloside low-dose group (14 mg/kg, i.g., similarly hereinafter), asperuloside high-dose group (28 mg/kg), high dose of asperuloside (28 mg/kg)+pc-NC (empty plasmid, 50 µg, via tail vein, similarly hereinafter) group, and high dose of asperuloside (28 mg/kg)+pc-SphK1 (SphK1 overexpression plasmid, 50 µg) group, with 12 rats in each group. Another 12 rats were fed with a normal diet as control group. Each group was given relevant medicine or plasmid intragastrically once a day or via tail vein twice a week, for 3 consecutive weeks. After the last medication, the levels of blood lipid indexes [total cholesterol (TC), triglyceride (TG), and free fatty acid (FFA)
]
and liver function indexes [aspartate transaminase (AST) and alanine transaminase (ALT)
]
were detected in each group. The pathological changes of liver tissue and liver fibrosis in rats were also observed in each group. The levels of serum fibrosis-related factors [procollagen type Ⅲ (PCⅢ), collagen type Ⅳ (Ⅳ-Col), laminin (LN)
]
, pro-fibrotic factor [transforming growth factor-β
1
(TGF-β
1
)
]
, and pro-inflammatory factors [interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS), IL-6
]
of rats were determined in each group. The expressions of collagen formation-related proteins (Ⅰ-Col, Ⅳ-Col) and SphK1/S1P pathway-related proteins in the liver tissues of rats were detected in each group.
RESULTS
2
Compared with control group, the liver tissue of rats in model group showed significant pathological damage; the NAFLD activity score, liver tissue collagen volume fraction, serum levels of TC, TG, FFA, AST, ALT, PCⅢ, Ⅳ-Col, LN, TGF-β
1
, IL-1β, iNOS and IL-6, and protein expressions of Ⅰ-Col, Ⅳ-Col, SphK1 and S1P in liver tissue were greatly increased (
P
<0.05). Compared with the model group, the liver tissue pathological damage symptoms of rats in asperuloside low-dose and high-dose groups were improved, and the above indexes were all reduced significantly (
P
<0.05); mor
eover, the high-dose group had a better effect (
P
<0.05). Compared to asperuloside high-dose group, high dose of asperuloside+pc-NC group, the pathological damage of liver tissue symptoms in rats were aggravated in high dose of asperuloside+pc-SphK1 group, and the above indexes were all increased significantly (
P
<0.05).
CONCLUSIONS
2
Asperuloside can reduce the expressions of pro-fibrotic factor, pro-inflammatory factors and collagen formation-related proteins by inhibiting the activity of SphK1/S1P signaling pathway, thus alleviating liver fibrosis in NAFLD rats.
TINCOPA M A , LOOMBA R . Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis [J ] . Lancet Gastroenterol Hepatol , 2023 , 8 ( 7 ): 660 - 670 .
HAN S K , BAIK S K , KIM M Y . Non-alcoholic fatty liver disease:definition and subtypes [J ] . Clin Mol Hepatol , 2023 , 29 ( Suppl. ): S5 - S16 .
RINELLA M E , NEUSCHWANDER-TETRI B A , SIDDIQUI M S , et al . AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease [J ] . Hepatology , 2023 , 77 ( 5 ): 1797 - 1835 .
HAMMERICH L , TACKE F . Hepatic inflammatory responses in liver fibrosis [J ] . Nat Rev Gastroenterol Hepatol , 2023 , 20 ( 10 ): 633 - 646 .
TAKESHITA Y , HONDA M , HARADA K , et al . Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes:a randomized,48-week,open-label,active-controlled trial [J ] . Diabetes Care , 2022 , 45 ( 9 ): 2064 - 2075 .
FENG F Z , GONG W Y , LI S Y , et al . Inhibitory effect of resveratrol on LPS-induced glomerular mesangial cells proliferation and TGF-β 1 expression via sphingosine kinase 1 pathway [J ] . Chin J Integr Med , 2023 , 29 ( 6 ): 500 - 507 .
ZHOU Z S , KONG C F , SUN J R , et al . Fisetin ameliorates alcohol-induced liver injury through regulating SIRT1 and SphK1 pathway [J ] . 2022 , 50 ( 8 ): 2171 - 2184 .
ABDELRAHEEM K M , YOUNIS N N , SHAHEEN M A , et al . Raspberry ketone improves non-alcoholic fatty liver disease induced in rats by modulating sphingosine kinase/sphingosine-1-phosphate and toll-like receptor 4 pathways [J ] . J Pharm Pharmacol , 2023 , 75 ( 7 ): 985 - 994 .
UCZAY M , PFLÜGER P , PICADA J N , et al . Geniposide and asperuloside alter the COX-2 and GluN2B receptor expression after pilocarpine-induced seizures in mice [J ] . Naunyn Schmiedebergs Arch Pharmacol , 2023 , 396 ( 5 ): 951 - 962 .
CHEN Q , ZHANG Q J , AMROUCHE A T , et al . Asperuloside,the bioactive compound in the edible Eucommia ulmoides male flower,delays muscle aging by daf-16 media- ted improvement in mitochondrial dysfunction [J ] . Food Funct , 2023 , 14 ( 12 ): 5562 - 5575 .
SHEN Q , CHEN Y E , SHI J X , et al . Asperuloside allevia- tes lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome [J ] . Eur J Pharmacol , 2023 , 942 : 175504 .
李芳 , 陈华伟 , 钟军华 , 等 . 槲皮苷对非酒精性脂肪肝大鼠肝纤维化和炎症作用研究 [J ] . 中国临床药理学杂志 , 2023 , 39 ( 12 ): 1753 - 1757 .
LI F , CHEN H W , ZHONG J H , et al . Effect of quercitrin on liver fibrosis and inflammation in non-alcoholic fatty liver rats [J ] . Chin J Clin Pharmacol , 2023 , 39 ( 12 ): 1753 - 1757 .
丁静 , 张斌 , 魏冬梅 , 等 . 盐酸小檗碱对非酒精性脂肪肝大鼠肝脏氧化应激水平及Nrf2表达的影响 [J ] . 免疫学杂志 , 2020 , 36 ( 3 ): 201 - 207 .
DING J , ZHANG B , WEI D M , et al . Effects of berberine hydrochloride on liver oxidative stress and nuclear Nrf2 expression in rats with nonalcoholic fatty liver disease [J ] . Immunol J , 2020 , 36 ( 3 ): 201 - 207 .
LEE K C , WU P S , LIN H C . Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis [J ] . Clin Mol Hepatol , 2023 , 29 ( 1 ): 77 - 98 .
FAN X D , ZHOU C , HUANG C , et al . Asperuloside ameliorates lipopolysaccharide-induced primary human perio- dontal ligament cell injury by decreasing TLR4 expression and NF-κB activation [J ] . Arch Oral Biol , 2021 , 129 : 105199 .
KONG Z Y , LIU C H , OLATUNJI O J . Asperuloside attenuates cadmium-induced toxicity by inhibiting oxidative stress,inflammation,fibrosis and apoptosis in rats [J ] . Sci Rep , 2023 , 13 ( 1 ): 5698 .
JOZEFCZUK E , SZCZEPANIAK P , GUZIK T J , et al . Silencing of Sphingosine kinase 1 affects maturation pathways in mouse neonatal cardiomyocytes [J ] . Int J Mol Sci , 2021 , 22 ( 7 ): 3616 .
MONTEFUSCO D , JAMIL M , MACZIS M A , et al . Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of NASH [J ] . Mol Metab , 2022 , 62 : 101523 .
0
浏览量
228
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621